PL442001A1 - Diagnostic test for early detection of breast cancer in women based on the assessment of arsenic concentrations in the blood and selected genotypes - Google Patents

Diagnostic test for early detection of breast cancer in women based on the assessment of arsenic concentrations in the blood and selected genotypes

Info

Publication number
PL442001A1
PL442001A1 PL442001A PL44200120A PL442001A1 PL 442001 A1 PL442001 A1 PL 442001A1 PL 442001 A PL442001 A PL 442001A PL 44200120 A PL44200120 A PL 44200120A PL 442001 A1 PL442001 A1 PL 442001A1
Authority
PL
Poland
Prior art keywords
breast cancer
blood
assessment
diagnostic test
early detection
Prior art date
Application number
PL442001A
Other languages
Polish (pl)
Other versions
PL242925B1 (en
Inventor
Jan LUBIŃSKI
Cezary Cybulski
Jacek Gronwald
Tomasz Huzarski
Anna Jakubowska
Katarzyna Białkowska
Wojciech MARCINIAK
Róża Derkacz
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL442001A priority Critical patent/PL242925B1/en
Publication of PL442001A1 publication Critical patent/PL442001A1/en
Publication of PL242925B1 publication Critical patent/PL242925B1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Nieoczekiwanie ustalono, że istnieje korelacja między stężeniem arsenu we krwi pełnej przy jednoczesnej ocenie wybranych genotypów z bardzo wysoką częstością występowania raka piersi u kobiet w populacji polskiej.Unexpectedly, it was found that there is a correlation between the concentration of arsenic in whole blood while evaluating selected genotypes with a very high incidence of breast cancer in women in the Polish population.

PL442001A 2020-05-14 2020-05-14 Diagnostic test for early detection of breast cancer in women based on the assessment of arsenic concentrations in the blood and selected genotypes PL242925B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL442001A PL242925B1 (en) 2020-05-14 2020-05-14 Diagnostic test for early detection of breast cancer in women based on the assessment of arsenic concentrations in the blood and selected genotypes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL442001A PL242925B1 (en) 2020-05-14 2020-05-14 Diagnostic test for early detection of breast cancer in women based on the assessment of arsenic concentrations in the blood and selected genotypes

Publications (2)

Publication Number Publication Date
PL442001A1 true PL442001A1 (en) 2022-12-19
PL242925B1 PL242925B1 (en) 2023-05-15

Family

ID=84487959

Family Applications (1)

Application Number Title Priority Date Filing Date
PL442001A PL242925B1 (en) 2020-05-14 2020-05-14 Diagnostic test for early detection of breast cancer in women based on the assessment of arsenic concentrations in the blood and selected genotypes

Country Status (1)

Country Link
PL (1) PL242925B1 (en)

Also Published As

Publication number Publication date
PL242925B1 (en) 2023-05-15

Similar Documents

Publication Publication Date Title
MX2020009278A (en) TESTS TO DETECT NEURODEGENERATION.
GB2440470A (en) Devices and methods for sample collection and analysis
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
ZA202300353B (en) Lateral flow assay device for detection of analytes and method of detection thereof
AR048031A1 (en) METHODS TO ESTIMATE THE NEED AND EFFECTIVENESS OF ANTIOXIDANT THERAPY
PL442001A1 (en) Diagnostic test for early detection of breast cancer in women based on the assessment of arsenic concentrations in the blood and selected genotypes
Pietruski et al. A novel computer system for the evaluation of nasolabial morphology, symmetry and aesthetics after cleft lip and palate treatment. Part 1: General concept and validation
TN2022000166A1 (en) Adjustment method for adjusting a setup for an analytical method
PL442000A1 (en) Diagnostic test for early detection of colorectal cancer in women based on the assessment of arsenic concentrations in the blood and selected genotypes
EA202090439A1 (en) METHODS AND MATERIALS FOR ASSESSMENT AND TREATMENT OF CANCER
WO2025096779A3 (en) Methods of treatment with a myosin inhibitor using protein levels
WO2019170545A8 (en) Means for the quantitative determination of an analyte concentration in a patient's urine sample
MX2021013715A (en) Multiplex assay for determining the ãŸ-amyloid 42/40 ratio in human plasma specimens.
RU2007119815A (en) METHOD FOR DETECTING RISK GROUPS OF BREAST CANCER RECIDIVITY AND METASTASES
ECSP23053645A (en) METHODS FOR THE DETECTION OF ANTI-DRUG ANTIBODIES AGAINST FACTOR XI AND/OR FACTOR XIA ANTIBODIES
PL433946A1 (en) Diagnostic test for early cancer detection in women based on assessment of arsenic concentrations in blood and selected genotypes
MX2022005428A (en) Method, device, and kit for population screening for cancer, cancer recurrence and precancerous conditions in symptom free individuals.
WO2021159128A3 (en) Methods and kit for detection of analytes
PL441999A1 (en) Method of determining the risk of cancer in men depending on the ratio of concentrations of selected elements in the blood
Zonta et al. Semiconductor Gas Sensors to Analyze Fecal Exhalation as a Method for Colorectal Cancer Screening
PL437895A1 (en) Way to determine the risk of cancer in men according to the concentration of copper in the blood
MX2022002407A (en) METHOD, DEVICE AND KIT FOR DETECTION, FOR THE DETECTION OF MUCOSA CARBOHYDRATES AND ASSOCIATED CONDITIONS.
PL437899A1 (en) Way to determine the risk of cancer in men according to the concentration of lead in the blood
TR202110941A2 (en) A TEST METHOD FOR DIAGNOSING COVID-19 DISEASE
Davis Empirical Likelihood Confidence Intervals for the Sensitivity of a Continuous-Scale Diagnostic Test